King's College London has developed an experimental drug that improves the response of chemotherapy-resistant tumors by targeting a tumor defense protein.
Ana Maria Eftene
International
Foto: Pexels.com
Always see our news on Google
The drug KCL-HO-1i developed by researchers at King's College London has the potential to transform treatments for chemotherapy-resistant cancers. It works by neutralizing the protein heme oxygenase-1 (HO-1), which helps tumors protect themselves from chemotherapy and immune system attacks. Preclinical tests have shown that the drug can make tumors more responsive to chemotherapy, even in previously resistant cases. Designed for oral administration, KCL-HO-1i could begin human clinical trials in two years, with the potential to expand its applications in oncology.
Sources
Speranță pentru bolnavii de cancer: Un nou medicament sporește eficacitatea chimioterapiei chiar și în cazul tumorilor rezistente
A apărut pastila care dezarmează cancerul! Descoperirea care ar putea rescrie regulile chimioterapiei: Chiar și cele mai rezistente tumori răspund la tratament
Latest News
22:59
The Pentagon is asking the American defense industry to rapidly increase the production and delivery of weapons.
22:45
CNAS reveals fraud in the healthcare system: Fake consultations for vulnerable patients: "They forgot to ask if the patients are still alive"
22:38
A WHO medical supplies depot in Dnipro, Ukraine, was attacked and destroyed.
22:29
The police in Botoșani discovered a body buried in the yard of a house belonging to a man who went missing in April. His partner has been arrested for qualified murder.
22:05
Elon Musk refuses the use of Starlink by Ukraine for attacks in Russia
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
